<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125229</url>
  </required_header>
  <id_info>
    <org_study_id>045-1503-266</org_study_id>
    <nct_id>NCT00125229</nct_id>
  </id_info>
  <brief_title>Cerebral Hemodynamic Effects of Hypertonic Solutions in Severely Head-Injured Patients</brief_title>
  <official_title>Cerebral Hemodynamic Effects of Hypertonic Solutions in Severely Head-Injured Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <brief_summary>
    <textblock>
      This is a clinical study comparing the physiologic effects of two hypertonic solutions
      (mannitol, hypertonic saline) with a particular emphasis on changes in cerebral blood flow in
      patients with intracranial hypertension following serious traumatic brain injury (TBI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study comparing effects of two hypertonic solutions (mannitol, 6.4% hypertonic
      saline) on intracranial hypertension, cerebral blood flow, serum/urine osmolarity in patients
      with increased intracranial pressure caused by traumatic brain injury. The study is conducted
      during first 72 hours after the injury without any interference with standard medical
      treatment as performed at the institution. When the hypertonic solution is indicated by
      caregiver, the study team is informed and performs a set of physiologic bedside measurements
      including evaluation of cerebral blood flow and changes in plasma and urine osmolarity. The
      study is noninvasive and the study protocol does not hamper, in any way, standard care of
      treatment for these patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Dr. Hladky died Sept 2006 prior to study completion
  </why_stopped>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Intracranial Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic Saline</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe TBI (motor Glasgow Coma Scale [GCS] score &lt; 5)

          -  Age &gt; 18 years

          -  Health care provider indicated a treatment of intracranial hypertension using
             hyperosmotic agent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe TBI (motor Glasgow Coma Scale [GCS] score &lt; 5)

          -  Age &gt; 18 years

          -  Health care provider indicated a treatment of intracranial hypertension using
             hyperosmotic agent

        Exclusion Criteria:

          -  Brain dead (GCS 3, fixed dilated pupils)

          -  Life-threatening systemic injuries (AIS &gt; 4 in an organ system other than brain); AIS
             = Abbreviated Injury Score

          -  Hypotension not responsive to fluid resuscitation and low doses of dopamine

          -  Clinical or imaging sign/suspicion for internal carotid artery injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Hlatky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Neurosurgical Sciences - UTHSC San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Neurosurgery Sciences - UTHSCSA - Surgical Intensive Care Unit (SICU)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Miller JD, Becker DP, Ward JD, Sullivan HG, Adams WE, Rosner MJ. Significance of intracranial hypertension in severe head injury. J Neurosurg. 1977 Oct;47(4):503-16.</citation>
    <PMID>903804</PMID>
  </reference>
  <reference>
    <citation>Doyle JA, Davis DP, Hoyt DB. The use of hypertonic saline in the treatment of traumatic brain injury. J Trauma. 2001 Feb;50(2):367-83. Review.</citation>
    <PMID>11242309</PMID>
  </reference>
  <reference>
    <citation>Wade CE, Kramer GC, Grady JJ, Fabian TC, Younes RN. Efficacy of hypertonic 7.5% saline and 6% dextran-70 in treating trauma: a meta-analysis of controlled clinical studies. Surgery. 1997 Sep;122(3):609-16.</citation>
    <PMID>9308620</PMID>
  </reference>
  <reference>
    <citation>Valadka AB, Robertson CS. Should we be using hypertonic saline to treat intracranial hypertension? Crit Care Med. 2000 Apr;28(4):1245-6. Review.</citation>
    <PMID>10809326</PMID>
  </reference>
  <reference>
    <citation>Berger S, Schürer L, Härtl R, Deisböck T, Dautermann C, Murr R, Messmer K, Baethmann A. 7.2% NaCl/10% dextran 60 versus 20% mannitol for treatment of intracranial hypertension. Acta Neurochir Suppl (Wien). 1994;60:494-8.</citation>
    <PMID>7526628</PMID>
  </reference>
  <reference>
    <citation>Worthley LI, Cooper DJ, Jones N. Treatment of resistant intracranial hypertension with hypertonic saline. Report of two cases. J Neurosurg. 1988 Mar;68(3):478-81.</citation>
    <PMID>3343621</PMID>
  </reference>
  <reference>
    <citation>Qureshi AI, Suarez JI, Bhardwaj A, Mirski M, Schnitzer MS, Hanley DF, Ulatowski JA. Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: Effect on intracranial pressure and lateral displacement of the brain. Crit Care Med. 1998 Mar;26(3):440-6.</citation>
    <PMID>9504569</PMID>
  </reference>
  <reference>
    <citation>Qureshi AI, Wilson DA, Traystman RJ. Treatment of elevated intracranial pressure in experimental intracerebral hemorrhage: comparison between mannitol and hypertonic saline. Neurosurgery. 1999 May;44(5):1055-63; discussion 1063-4.</citation>
    <PMID>10232539</PMID>
  </reference>
  <reference>
    <citation>Vialet R, Albanèse J, Thomachot L, Antonini F, Bourgouin A, Alliez B, Martin C. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Crit Care Med. 2003 Jun;31(6):1683-7.</citation>
    <PMID>12794404</PMID>
  </reference>
  <reference>
    <citation>Battison C, Andrews PJ, Graham C, Petty T. Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med. 2005 Jan;33(1):196-202; discussion 257-8.</citation>
    <PMID>15644669</PMID>
  </reference>
  <reference>
    <citation>Cruz J, Minoja G, Okuchi K, Facco E. Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial. J Neurosurg. 2004 Mar;100(3):376-83.</citation>
    <PMID>15035271</PMID>
  </reference>
  <reference>
    <citation>Tseng MY, Al-Rawi PG, Pickard JD, Rasulo FA, Kirkpatrick PJ. Effect of hypertonic saline on cerebral blood flow in poor-grade patients with subarachnoid hemorrhage. Stroke. 2003 Jun;34(6):1389-96. Epub 2003 May 1.</citation>
    <PMID>12730557</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2005</study_first_submitted>
  <study_first_submitted_qc>July 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2005</study_first_posted>
  <last_update_submitted>June 22, 2012</last_update_submitted>
  <last_update_submitted_qc>June 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertonic Saline</keyword>
  <keyword>Mannitol</keyword>
  <keyword>Intracranial hypertension</keyword>
  <keyword>Cerebral blood flow</keyword>
  <keyword>Traumatic brain injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Intracranial Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

